Trizepatide

Trizepatide

Trizepatide represents a new frontier in diabetes and obesity treatment, offering unprecedented benefits by targeting two incretin pathways.

Get your 12-week supply for:

$1,349.00

More about DripIV’s

Trizepatide

Trizepatide is a novel dual GIP and GLP-1 receptor agonist under investigation for the treatment of type 2 diabetes and obesity. It offers a new approach by combining the effects of two incretin hormones.

$1,349 (12-week supply)

• Superior Glycemic Control: Enhances blood sugar management in type 2 diabetes.
• Significant Weight Loss: Promotes weight reduction through dual hormonal action.
• Cardiovascular Health: Potential to improve cardiovascular outcomes in diabetic patients.
• Innovative Treatment: Combines GIP and GLP-1 receptor agonism for enhanced efficacy.